Patents by Inventor Yihong Ye

Yihong Ye has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment
    Patent number: 8637560
    Abstract: The present invention features imidazolidinone compounds and pharmaceutical compositions of imidazolidinone compounds. The compounds of the invention are utilized in methods of treating a deubiquitination-related disorder in a subject and inhibiting p97-associated deubiquitination.
    Type: Grant
    Filed: July 18, 2008
    Date of Patent: January 28, 2014
    Assignee: The United States of America as Represented by the Secretary of the Department of Health and Human Services
    Inventors: William Trenkle, Adrian Wiestner, Qiuyan Wang, Yihong Ye, Helena Mora-Jensen
  • Hydrazone and diacyl hydrazine compounds and methods of use
    Patent number: 8518968
    Abstract: Disclosed herein are novel hydrazone and diacyl hydrazine derivatives that are inhibitors of the endoplasmic reticulum-associated protein degradation (ERAD) pathway. Also disclosed are hydrazone and diacyl hydrazine derivatives as potent and selective inhibitors of the p97 ATPase. These agents provide useful tools for the study of protein degradation and other processes involving p97. Methods of treating diseases or disorders for which p97 inhibition and/or ER stress induction is an effective treatment with certain hydrazone and diacyl hydrazine derivatives are also disclosed.
    Type: Grant
    Filed: December 3, 2010
    Date of Patent: August 27, 2013
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Adrian Wiestner, Yihong Ye, Qiuyan Wang, William C. Trenkle, Bidhan A. Shinkre
  • HYDRAZONE AND DIACYL HYDRAZINE COMPOUNDS AND METHODS OF USE
    Publication number: 20120316198
    Abstract: Disclosed herein are novel hydrazone and diacyl hydrazine derivatives that are inhibitors of the endoplasmic reticulum-associated protein degradation (ERAD) pathway. Also disclosed are hydrazone and diacyl hydrazine derivatives as potent and selective inhibitors of the p97 ATPase. These agents provide useful tools for the study of protein degradation and other processes involving p97. Methods of treating diseases or disorders for which p97 inhibition and/or ER stress induction is an effective treatment with certain hydrazone and diacyl hydrazine derivatives are also disclosed.
    Type: Application
    Filed: December 3, 2010
    Publication date: December 13, 2012
    Applicant: The United States of American, as Represented by the Secretary, Dept. of Health and Human Services
    Inventors: Adrian Wiestner, Yihong Ye, Qiuyan Wang, William C. Trenkle, Bidhan A. Shinkre
  • IMIDAZOLIDINONE COMPOUNDS, METHODS TO INHIBIT DEUBIQUITINATION AND METHODS OF TREATMENT
    Publication number: 20100286091
    Abstract: The present invention features imidazolidinone compounds and pharmaceutical compositions of imidazolidinone compounds. The compounds of the invention are utilized in methods of treating a deubiquitination-related disorder in a subject and inhibiting p97-associated deubiquitination.
    Type: Application
    Filed: July 18, 2008
    Publication date: November 11, 2010
    Inventors: Adrian Wiestner, William Trenkle, Qiuyan Wang, Yihong Ye, Helena Mora-Jensen